LXRX Lexicon Pharmaceuticals Inc.

4.68
-0.04  -1%
Previous Close 4.72
Open 4.71
52 Week Low 1.03
52 Week High 9.65
Market Cap $675,734,899
Shares 144,387,799
Float 67,280,838
Enterprise Value $541,284,387
Volume 392,888
Av. Daily Volume 644,626
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Sotagliflozin
Heart failure
NDA Filing
NDA Filing
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
LX9211 (RELIEF-PHN 1)
Post-herpetic neuralgia
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
LX9211 (RELIEF-DPN 1)
Diabetic Peripheral Neuropathy
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Sotagliflozin
Type 1 Diabetes
CRL
CRL
CRL issued March 22, 2019. Appeal rejected by FDA - December 2, 2019.

Latest News

  1. THE WOODLANDS, Texas, May 26, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, Lexicon's president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.

    A webcast of the event will be available in the "Events" section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more…

    THE WOODLANDS, Texas, May 26, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, Lexicon's president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.

    A webcast of the event will be available in the "Events" section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements," including statements relating to Lexicon's financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    For Inquiries:

    Chas Schultz

    Executive Director, Corporate Communications and Investor Relations

    Lexicon Pharmaceuticals

    (281) 863-3421



    Primary Logo

    View Full Article Hide Full Article
  2. THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology's 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021:

    • Sunday, May 16, 2021, 10:45 am ET; Session 902: "Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review"
      • "Sotagliflozin Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the SOLOIST-WHF Trial" (10:57 am-11:07 am ET). Presented by Michael Szarek, Ph.D.
    • Monday, May 17, 2021, 8:00 am ET; Session 410: "Late-Breaking Clinical Trials IV"
      • "Benefits of Sodium Glucose Co-transporter-1/2…

    THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the American College of Cardiology's 70th Annual Scientific Session (ACC.21) being held May 15, 2021 through May 17, 2021:

    • Sunday, May 16, 2021, 10:45 am ET; Session 902: "Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review"
      • "Sotagliflozin Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the SOLOIST-WHF Trial" (10:57 am-11:07 am ET). Presented by Michael Szarek, Ph.D.
    • Monday, May 17, 2021, 8:00 am ET; Session 410: "Late-Breaking Clinical Trials IV"
      • "Benefits of Sodium Glucose Co-transporter-1/2 Inhibition with Sotagliflozin Across the Full Spectrum of Ejection Fraction, Including Heart Failure with Preserved Ejection Fraction" (8:00 am-8:10 am ET). Presented by Deepak Bhatt, M.D., M.P.H.

    About Sotagliflozin

    Discovered using Lexicon's unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements," including statements relating to Lexicon's financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    For Inquiries:

    Chas Schultz

    Executive Director, Corporate Communications and Investor Relations

    Lexicon Pharmaceuticals

    (281) 863-3421

     



    Primary Logo

    View Full Article Hide Full Article
  3. Conference Call and Webcast at 5:00 pm Eastern Time

    THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones.

    "We continue to enroll patients in our two proof-of-concept Phase 2 clinical studies for LX9211 in neuropathic pain and look forward to results from these studies by the end of the year," said Lonnel Coats, Lexicon's president and chief executive officer. "We are also very pleased with the regulatory feedback received from the FDA on sotagliflozin in heart failure and we are moving expeditiously forward with a planned NDA filing in that indication this year."

    First Quarter

    Conference Call and Webcast at 5:00 pm Eastern Time

    THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones.

    "We continue to enroll patients in our two proof-of-concept Phase 2 clinical studies for LX9211 in neuropathic pain and look forward to results from these studies by the end of the year," said Lonnel Coats, Lexicon's president and chief executive officer. "We are also very pleased with the regulatory feedback received from the FDA on sotagliflozin in heart failure and we are moving expeditiously forward with a planned NDA filing in that indication this year."

    First Quarter Highlights

    LX9211

    • Patient enrollment continued in RELIEF-DPN-1, a Phase 2 clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. Enrollment is expected to total approximately 300 patients at approximately 40 clinical sites.
    • Patient enrollment continued in RELIEF-PHN 1, a Phase 2 clinical study of LX9211 for the treatment of post-herpetic neuralgia. Enrollment is expected to total approximately 74 patients at approximately 20 clinical sites.

    Sotagliflozin

    • U.S. Food and Drug Administration (FDA) provided regulatory feedback that the results of the SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

    2021 Anticipated Milestones and Events

    • NDA filing for sotagliflozin in heart failure.
    • Active efforts to secure strategic alliance for sotagliflozin in heart failure.
    • Phase 2 study results from RELIEF-DPN-1 for LX9211 in diabetic peripheral neuropathic pain.
    • Phase 2 study results from RELIEF-PHN-1 for LX9211 in post-herpetic neuralgia.
    • Additional publications for sotagliflozin and LX9211.

    First Quarter 2021 Financial Highlights

    Revenues: Revenues for the three months ended March 31, 2021 were negligible as compared to $8.0 million for the corresponding period in 2020, primarily due to the absence of product revenues as a result of the sale of XERMELO during the third quarter of 2020.

    Research and Development (R&D) Expenses: Research and development expenses for the three months ended March 31, 2021 decreased to $12.6 million from $55.2 million for the corresponding period in 2020, primarily due to decreases in external clinical development costs related to sotagliflozin resulting from the completion of clinical studies.

    Selling, General and Administrative (SG&A) Expenses: Selling, general and administrative expenses for the three months ended March 31, 2021 decreased to $8.3 million from $14.7 million for the corresponding period in 2020, primarily due to lower salaries and benefit costs as a result of reductions in personnel in September 2020 and lower marketing expenses.

    Net Loss: Net loss for the three months ended March 31, 2021 was $21.0 million, or $0.15 per share, as compared to a net loss of $66.6 million, or $0.63 per share, in the corresponding period in 2020. For the three months ended March 31, 2021 and 2020, net income included non-cash, stock-based compensation expense of $2.9 million and $4.4 million, respectively.

    Cash and Investments: As of March 31, 2021, Lexicon had $141.4 million in cash and investments, as compared to $152.3 million as of December 31, 2020.

    Conference Call and Webcast Information

    Lexicon management will hold a live conference call and webcast today at 5:00 pm ET / 4:00 pm CT to review its financial and operating results and to provide a general business update. The dial-in number for the conference call is 888-645-5785 (U.S./Canada) or 970-300-1531 (international). The conference ID for all callers is 8456671. The live webcast and replay may be accessed by visiting Lexicon's website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements," including statements relating to Lexicon's financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    Lexicon Pharmaceuticals, Inc.

    Selected Financial Data

    Consolidated Statements of Operations DataThree Months Ended March 31, 
    (In thousands, except per share data) 2021   2020 
     (Unaudited) 
    Revenues:     
    Net product revenue$-  $                 7,877 
    Collaborative agreements-  8 
    Royalties and other revenue27  114 
    Total revenues27  7,999 
    Operating expenses:     
    Cost of sales (including finite-lived intangible asset amortization)                          -                            568 
    Research and development, including stock-based compensation     
    of $1,286 and $2,176, respectively                 12,609                    55,181 
    Selling, general and administrative, including stock-based compensation     
    of $1,565 and $2,256, respectively8,257  14,688 
    Total operating expenses20,866  70,437 
    Loss from operations(20,839) (62,438)
    Interest expense(167) (5,131)
    Interest and other income, net48  958 
    Net loss$            (20,958) $             (66,611)
          
          
    Net loss per common share, basic and diluted$                 (0.15) $                  (0.63)
          
    Shares used in computing net loss per common share, basic and diluted143,379  106,536 
          
          
    Consolidated Balance Sheet DataAs of March 31,

    2021
      As of December 31, 2020 
    (In thousands)(Unaudited)    
          
    Cash and investments$            141,361  $             152,275 
    Property and equipment, net296  295 
    Goodwill44,543  44,543 
    Total assets193,260  203,788 
    Current and long-term debt11,660  11,646 
    Accumulated deficit(1,420,976) (1,400,018)
    Total stockholders' equity152,547  156,371 

    For Inquiries:

    Chas Schultz

    Executive Director, Corporate Communications and Investor Relations

    Lexicon Pharmaceuticals

    (281) 863-3421

     



    Primary Logo

    View Full Article Hide Full Article
  4. THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

    Dial-in Information
    U.S. Dial-in Number: (888) 645-5785
    International Dial-in Number:   (970) 300-1531
    Conference ID: 8892167

    Replay Information
    U.S. Dial-in Number: (855) 859-2056
    Replay International Dial-in Number: (404) 537-3406
    Conference ID: 8892167

    The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events

    THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

    Dial-in Information

    U.S. Dial-in Number: (888) 645-5785

    International Dial-in Number:   (970) 300-1531

    Conference ID: 8892167

    Replay Information

    U.S. Dial-in Number: (855) 859-2056

    Replay International Dial-in Number: (404) 537-3406

    Conference ID: 8892167

    The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements," including statements relating to Lexicon's financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211, sotagliflozin and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    For Inquiries:

    Chas Schultz

    Executive Director, Corporate Communications and Investor Relations

    Lexicon Pharmaceuticals

    (281) 863-3421



    Primary Logo

    View Full Article Hide Full Article
  5. THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, Lexicon's executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET.

    A webcast of the event will be available in the "Events" section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™…

    THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, Lexicon's executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET.

    A webcast of the event will be available in the "Events" section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks.

    About Lexicon Pharmaceuticals

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements," including statements relating to Lexicon's financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

    For Inquiries:

    Chas Schultz

    Executive Director, Corporate Communications and Investor Relations

    Lexicon Pharmaceuticals

    (281) 863-3421



    Primary Logo

    View Full Article Hide Full Article
View All Lexicon Pharmaceuticals Inc. News